Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Gazzah, A. [1 ]
Lee, J. S. [2 ]
Wang, E. [2 ]
Ternes, N. [3 ]
Wang, H. [2 ]
Boitier, E. [3 ]
Lartigau, A. [3 ]
Chadjaa, M. [3 ]
Dib, C. [3 ]
Muzard, G. [3 ]
Valence, S. [3 ]
Remaury, A. [3 ]
Palu, C. C. [4 ]
Bauchet, A-L. [3 ]
机构：
[1] Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71P
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [21] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A phase II study of nedaplatin (CDGP) and docetaxel (TXT) in patients with advanced non-small cell lung cancer (NSCLC)
    Fujino, S.
    Asada, Y.
    Nakano, Y.
    Suzumura, Y.
    Inoue, S.
    Nagao, T.
    Hajiro, T.
    Tezuka, N.
    Sawai, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Phase II study of dasatinib in patients with advanced non-small cell lung cancer
    Johnson, F. M.
    Bekele, B. N.
    Feng, L.
    Wistuba, I. I.
    Tang, X.
    Tran, H. T.
    Erasmus, J. J.
    Hwang, L.
    Takebe, N.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
  • [26] Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
    Casado, A
    Rosell, R
    GarciaGomez, R
    DiazRubio, E
    PerezManga, G
    Font, A
    Benavides, A
    Martin, M
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 415 - 417
  • [27] First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
    Gazzah, Anas
    Cousin, Sophie
    Boni, Valentina
    Ricordel, Charles
    Kim, Tae Min
    Kim, Jin-Soo
    Helissey, Carole
    Gardeazabal, Itziar
    Chadjaa, Mustapha
    Allard, Aurore
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer
    Evans, TRJ
    Mansi, JL
    Morgan, DAL
    Gyi, KM
    Banham, SW
    Milroy, R
    ONCOLOGY REPORTS, 1997, 4 (06) : 1337 - 1341
  • [29] ACTIVITY OF PATUPILONE IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
    Zatloukal, P.
    Mellemgaard, A.
    Sanchez, J. M.
    Perry, M. C.
    Hamm, J. T.
    Van Meerbeeck, J.
    DeLeo, J. J.
    Gao, B.
    Johri, A. R.
    Felip, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 109 - 109
  • [30] BIOMARKER PATTERN IN NEVER SMOKER PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Santos, Edgardo S.
    Ochoa, Roberto E.
    Bisneto, Jose Villasboas
    Gomez, Jorge E.
    Danenberg, Kathleen
    Raez, Luis E.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1111 - S1112
12345